Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On December14, 2016, the board of directors (the Board) of
Momenta Pharmaceuticals,Inc. (the Company) adopted the Momenta
Pharmaceuticals,Inc. Equity Award Retirement Policy (the
Retirement Policy) to provide for the treatment of options to
purchase shares of the Companys common stock (Options) and any
restricted stock units that the company in the future grants
subject to service-based (but not performance-based) vesting
conditions (RSUs) upon a participants qualifying retirement from
the Company.

Under the Retirement Policy, following the qualifying retirement
of any employee of the Company or non-employee member of the
Board (each, an Eligible Participant), the Eligible Participants
then-outstanding RSUs and Options will continue to vest during
the one year period following the retirement date. In addition,
the Eligible Participant will have until the first anniversary of
the retirement date (or 90 days following the date an Option
becomes first exercisable if such date is within the 90 days
preceding the first anniversary of the retirement date) to
exercise any vested Options, except that no Option may be
exercised following the date upon which it would have become
unexercisable under the applicable Option award agreement if the
Eligible Participant had maintained the applicable service
relationship with the Company. Benefits under the Retirement
Policy are conditioned upon an Eligible Participants continued
compliance with any non-competition, non-solicitation,
confidentiality or other restrictive covenants with the Company.

The Retirement Policy became effective on the date it was adopted
by the Board. The Board or its compensation committee may amend,
modify or terminate the Retirement Policy at any time.

The foregoing description of the Retirement Policy does not
purport to be complete and is qualified in its entirety by
reference to the text of the Amendment, which is filed as
Exhibit10.1 to this Current Report and incorporated herein by
reference.

Item 9.01. Financial Statements and
Exhibits.

(d) Exhibits.

About Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Recent Trading Information

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) closed its last trading session up +0.35 at 15.70 with 786,982 shares trading hands.